BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
    • Index insights
    • NME Digest
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Under threat: mRNA vaccine research
    • BioWorld at 35
    • Biopharma M&A scorecard
    • Bioworld 2025 review
    • BioWorld MedTech 2025 review
    • BioWorld Science 2025 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Coronavirus
    • More reports can be found here

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
BioWorld - Friday, January 16, 2026
Home » Authors » Mark McCarty

Articles by Mark McCarty

Washington roundup: More enforcement seen coming from inside and outside of FDA

May 4, 2010
By Mark McCarty

Entellus launches new sinus surgery unit with more reach

May 3, 2010
By Mark McCarty

Market Developments: CMS to cover NaF-18 PET for metastatic bone cancer under CED

May 1, 2010
By Mark McCarty

Washington roundup: CDRH revamps advisory panel voting, discussion procedures

April 29, 2010
By Mark McCarty

Schultz upbeat about devices but venture capitalist worried

April 27, 2010
By Mark McCarty

Shuren: systemic changes may at times trump immediate needs

April 26, 2010
By Mark McCarty
WASHINGTON – Jeff Shuren, the new director of the Center for Devices and Radiological Health has made extensive time in his schedule for communicating with industry, and this year's annual conference by the Food and Drug Law Institute (FDLI; Washington) served as yet another forum for the new device chief. He reviewed a number of issues raised by device makers since he took the job, but one comment he made may suggest something about why industry sees the center as less responsive. Shuren informed the audience that while agency employees are instructed to respond promptly to industry inquiries, other issues may supersede this and other short-term priorities. (Medical Device Daily)
Read More

Tyler advising FDA to fill in statutory voids aggressively

April 23, 2010
By Mark McCarty
WASHINGTON – FDA Commissioner Margaret Hamburg, MD, opened the plenary session on the first day of the 53rd Annual FDLI Conference, hosted by the Food and Drug Law Institute (FDLI; Washington), and she made it clear at the outset that the agency will not hesitate to ask Congress for additional statutory authority should she conclude that such a request would be appropriate. On the other hand, the agency's new chief counsel, Ralph Tyler, also made a point very clear, that his office would do its best to facilitate enforcement action even in the absence of direct statutory authority, assuming that the intended action does not explicitly run afoul of the statute. (Medical Device Daily)
Read More

Washington roundup: FDA announces initiative for medical devices for home use

April 22, 2010
By Mark McCarty

Washington roundup: Clawbacks offset updates for long-term, acute care hospitals

April 21, 2010
By Mark McCarty

Washington roundup: AHRQ says infections acquired in hospitals are still an issue

April 19, 2010
By Mark McCarty
Previous 1 2 … 486 487 488 489 490 491 492 493 494 … 578 579 Next

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for Jan 15, 2025.
  • Today's news in brief

    BioWorld MedTech
    BioWorld MedTech briefs for Jan. 15, 2026.
  • 3D rendering of antibody drug conjugated with cytotoxic payload

    ADCs’ breakout 2025 and their still-unfinished potential

    BioWorld
    Over the course of the year, and continuing into the latest scientific meetings, an extraordinary breadth of new antibody-drug conjugate (ADC) designs was...
  • Lung cancer illustration

    LINC01116 has prognostic value in lung cancer, study shows

    BioWorld MedTech
    Long noncoding RNAs (lncRNAs) have emerged as potential markers of disease, since they associate with proteins that regulate gene expression, translation or...
  • SERPINB1 as potential biomarker for spinocerebellar ataxia type 2

    BioWorld Science
    Researchers from Goethe-Universität and collaborators investigated novel molecular biomarker candidates for spinocerebellar ataxia type 2, a progressive...
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld MedTech
    • Today's news
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/Metabolic
    • Immune
    • Infection
    • Neurology/Psychiatric
    • NME Digest
    • Patents
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2026. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing